Cerapedics, a Westminster, Colo.-based orthobiologics company, completed a $22m financing.
The round was led by KCK Group.
The company intends to use the funds to accelerate commercialization and U.S. lumbar trial for i-FACTOR™ Peptide Enhanced Bone Graft.
Led by Glen A. Kashuba, chief executive officer, Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary biomimetic small peptide (P-15) technology platform. i‑FACTOR Peptide Enhanced Bone Graft is a biologic bone that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process.
The company received Premarket Approval (PMA) from the U.S. Food & Drug Administration for the use of i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion (ACDF) procedures. It has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion (TLIF) surgery.
In addition, Cerapedics also announced three new members of the company’s board of directors, including:
– Valeska Schroeder, Ph.D., managing director of the medical technologies division at KCK Group,
– Greg Garfield, J.D., senior managing director and head of the medical technologies division at KCK Group, and
– Nael Karim Kassar, investment partner at KCK Group.